Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 9M | 10M | 11M | 12M | 10M |
| Gross Profit | 9M | 10M | 11M | 12M | 10M |
| Operating Income | 2M | 3M | 3M | 5M | 4M |
| EBITDA | 109M | -104M | 139M | 62M | 6M |
| Net Income | 112M | -101M | 142M | 67M | 10M |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$18.29
+0.11% today
1Y Change
+12.73%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Payden Equity Income Fund Adviser Cl (PYVAX) is a fund with a market cap of $1.28B and listed on NASDAQ. The fund last traded around $18.29 and up 12.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include a dividend yield of 5.9%. Valuation already assumes a fairly strong business story at price/sales 139.2. Stock Foundry combines PYVAX price history, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PYVAX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PYVAX Max Drawdown
-7.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PYVAX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.4M
-9.8% YoY
FY Net Income
$9.7M
-85.4% YoY
Free Cash Flow
$0.0
Revenue Growth
-12.3%
EPS Growth
+209.5%
Gross Margin
100.0%
Net Margin
1213.7%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 9M | 10M | 11M | 12M | 10M |
| Gross Profit | 9M | 10M | 11M | 12M | 10M |
| Operating Income | 2M | 3M | 3M | 5M | 4M |
| EBITDA | 109M | -104M | 139M | 62M | 6M |
| Net Income | 112M | -101M | 142M | 67M | 10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 647M | 601M | 719M | 621M | 602M |
| Total Liabilities | 8M | 24M | 3M | 5M | 11M |
| Shareholder Equity | 639M | 576M | 715M | 617M | 591M |
| Total Debt | 0 | 0 | 0 | 0 | 93K |
| Net Debt | 0 | 0 | 0 | 0 | 93K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
0
Capital Expenditures
0
Free Cash Flow
0
Key ratios
Gross Margin
100.0%
Operating Margin
23.8%
Net Margin
1213.7%
ROE
18.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.